Predict your next investment

Venture Capital
haystack.vc

See what CB Insights has to offer

Investments

80

Portfolio Exits

15

Funds

5

About Haystack Fund

Haystack Fund is the investment vehicle of Semil Shah. It focuses on early-stage venture capital investments.

Haystack Fund Headquarter Location

38 Miller Avenue Suite 123

Mill Valley, California, 94941,

United States

415-868-5024

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Haystack Fund

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Haystack Fund in 1 CB Insights research brief, most recently on Sep 25, 2019.

Latest Haystack Fund News

Perlara Raises $7.4M in Equity Financing

Nov 1, 2017

Perlara , a South San Francisco, CA-based drug discovery platform company, closed a $7.4M round of equity financing. Backers included Pivotal Capital Alpha, Al-Hamra Group, Radical Investments, Homebrew Ventures, Haystack Fund and existing investors, including Y Combinator. Novartis participated in the financing under the terms of its research collaboration with Perlara. Led by founder and CEO Ethan Perlstein, PhD., Perlara is a public benefit corporation working to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. The company operates by embarking on discovery journeys called PerlQuests™ with families and patient organizations to develop treatments for rare diseases. The first PerlQuests target Niemann-Pick C Disease (NPC) and Niemann-Pick A Disease (NPA), lysosomal storage disorders, NGLY1 Deficiency, a metabolic disease related to proteasome-mediated degradation, and PMM2-CDG, a congenital disorder of glycosylation. What we are learning from the NPC PerlQuest may lead to drug candidates for Alzheimer’s disease. Its first PerlQuesters are Grace Science Foundation (NGLY1), Wylder Nation Foundation (NPA), and Maggie’s PMM2-CDG Cure, three pioneers in the search for treatments of rare diseases. The company, which has raised a total of $9.9M since inception in 2014, intends to use the funds to advance programs forward, discover novel lead compounds for its first three PerlQuest partners, and double its disease pipeline with the launch of six new PerlQuests. FinSMEs 01/11/2017

Haystack Fund Investments

80 Investments

Haystack Fund has made 80 investments. Their latest investment was in LatchBio as part of their Series A on June 6, 2022.

CBI Logo

Haystack Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/2/2022

Series A

LatchBio

$28M

Yes

4

2/23/2022

Series B

Redpanda

$50M

Yes

15

2/14/2022

Series B

Databook

$50M

No

14

1/28/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/8/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/2/2022

2/23/2022

2/14/2022

1/28/2022

12/8/2021

Round

Series A

Series B

Series B

Series A

Series B

Company

LatchBio

Redpanda

Databook

Subscribe to see more

Subscribe to see more

Amount

$28M

$50M

$50M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

15

14

10

10

Haystack Fund Portfolio Exits

15 Portfolio Exits

Haystack Fund has 15 portfolio exits. Their latest portfolio exit was BentoBox on October 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/18/2021

Acquired

$99M

4

7/14/2021

Acquired

$99M

11

6/21/2021

Acquired

$99M

16

3/4/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/18/2021

7/14/2021

6/21/2021

3/4/2021

12/18/2020

Exit

Acquired

Acquired

Acquired

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

11

16

10

10

Haystack Fund Fund History

5 Fund Histories

Haystack Fund has 5 funds, including Haystack Ventures V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/5/2019

Haystack Ventures V

Early-Stage Venture Capital

Closed

$50M

2

5/31/2017

Haystack Ventures IV

Subscribe to see more

Subscribe to see more

10

12/31/2015

Haystack Fund III

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2014

Haystack Fund II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2013

Haystack Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/5/2019

5/31/2017

12/31/2015

12/31/2014

12/31/2013

Fund

Haystack Ventures V

Haystack Ventures IV

Haystack Fund III

Haystack Fund II

Haystack Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

$99M

$99M

Sources

2

10

10

10

10

Haystack Fund Team

1 Team Member

Haystack Fund has 1 team member, including current Managing Partner, Semil Shah.

Name

Work History

Title

Status

Semil Shah

Managing Partner

Current

Name

Semil Shah

Work History

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.